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diarrhea, dyspnea, fatigue, insomnia, nausea, neuropathy, pain, and vomiting. The
final recommendations provide guidance on selection of PRO measures, imple-
mentation methods and data analysis/reporting considerations. CONCLUSIONS:
The patient perspective is an essential component of CER. Standardizing PRO data
collection in oncology trials will lead to greater comparability and improved pa-
tient-centered decision-making.
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OBJECTIVES: Examine knowledge and information seeking behaviors towards
blood transfusions among individuals with metastatic or recurrent cancer.
METHODS: An online survey was conducted from a nationally representative pa-
tient panel in 1Q2011. All respondents were 18 years and diagnosed with Cancer
by a physician. Participants were asked about their blood transfusion history, in-
formation seeking behaviors, and knowledge about blood transfusion. RESULTS: A
total of 206 individuals responded to survey. 65% (n133) were female and 25%
(n52) were over 55 years; 55% (n114) were anemic and 45% (92) not anemic. 62%
(n128) had received blood transfusion, whereas, 38% (n78) had no transfusions.
Top two sources of information are doctor (85%) and Internet (78%). Among those
previously transfused, 74% received right amount of information, whereas, 11%
received too little information, and 15% received toomuch information. More than
90% of transfused indicated they knew the reasons for and benefits of getting a
blood transfusion. Less than two-thirds received information about the costs. Over
65% of not transfused said that it is extremely important to know risks of infec-
tions, right blood type and screening techniques. Among previously transfused,
about 70% agreed that they made an informed choice about receiving blood trans-
fusions. Among the previously transfused, 78% agree that they knew the benefits
compared with 68% not transfused. About 68% of transfused and not transfused
agree they knew the risks of blood transfusion. CONCLUSIONS: Doctor’s office and
internet are primary sources of information about blood transfusions. Gaps in
knowledge exist about benefits, risks, and costs of blood transfusions. A significant
number feel that they need more information about blood transfusion to make an
informed choice. Providers should consider adopting shared-decisionmakingwith
their patients.
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OBJECTIVES: According to the FDA Patient-reported outcome (PRO) Guidance, ev-
idence of input from the appropriate population during the development of a PRO
measure is critical to determine whether a measure is applicable. A literature re-
view was conducted to identify the symptoms and impacts (concepts) of brain
metastases (BM) and the key PRO measures used in BM to compare their develop-
ment and content validity. METHODS: Literature searches were conducted using
MEDLINE®. PRO measures were reviewed for patient input and the concepts re-
ported in the clinical literature on patients with BM were compared to those in-
cluded in the identified PRO measures. RESULTS: A total of 34 concepts and seven
key PROmeasures used in BM (Functional Assessment of Cancer Therapy- General
[FACT-G], FACT-Brain Tumor [FACT-Br], FACT-Brain Symptom Index [FBrSI], Euro-
pean Organization for Research and Treatment of Cancer-Quality of Life Question-
naire [EORTC-QLQ-C30], EORTC-Brain cancer module [EORTC QLQ-BN20], the
EORTC- palliative care cancer module [EORTC QLQ-C15-PAL] and the M.D. Ander-
son Symptom Inventory-Brain Tumor Module [MDASI-BT]) were reviewed. The
major limitation of all measures reviewed is that the items of thesemeasures were
not developed based on qualitative interviews with BM patients. In addition, these
measures include concepts that were not related to BM per se as identified in the
literature (e.g. itchy skin); some concepts found in the literature were not included
in these instruments (e.g. dizziness). CONCLUSIONS: Review of the seven PRO
measures used in patients with BM found that none of the measures have docu-
mented patient input in their development. The gaps between concepts reported in
the literature and the PRO measures suggest the need for direct patient input in
development of suchmeasures in order to be comprehensive and yet specific to the
target population.
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OBJECTIVES: COMFORT-I is a Phase III randomized, double-blind, placebo-con-
trolled study of ruxolitinib in patients with myelofibrosis. The placebo arm pro-
vides a controlled setting to assess changes in symptomatic burden and other
patient-reported outcomes (PROs) among patients not receiving myelofibrosis
therapy. METHODS: A total of 154 patients with intermediate-2 or high-risk my-
elofibrosis were randomized to placebo after a 28-day washout of previous myelo-
fibrosis therapies. Using a Total Symptom Score (TSS), myelofibrosis symptoms
(night sweats, itching, abdominal discomfort, pain under ribs on left side, early
satiety, and bone/muscle pain) were measured using the modified Myelofibrosis
Symptom Assessment Form v2.0. Other PRO measures included the EORTC QLQ-
C30 (100-point scale), PROMIS Fatigue Scale (100-point scale), and Patient Global
Impression of Change (PGIC; 7-point scale: 1very much improved, 7very much
worse, 4no change). Patients who withdrew or crossed over to active treatment
before a study visit were not included in analyses for that visit or subsequent visits.
RESULTS: The study included 35% intermediate-2 and 65% high-risk patients (me-
dian 2.5 years since diagnosis). By week 24, mean TSS worsened by 42% from
baseline. EORTC QLQ-C30 Global Health Status and functional subscale scores also
worsened from baseline to week 24, with the greatest changes in Role Functioning
(mean change  -11.1) and Social Functioning (-9.0); mean PROMIS Fatigue score
worsened by 9.1%. Mean PGIC score was 4.2 at week 24; 40.2% of patients perceived
their condition to be worse and 29.9% unchanged. As measured by MRI/CT, spleen
volume (closely related to some myelofibrosis symptoms) increased by a mean of
8.1% at week 24. CONCLUSIONS: In concert with increased spleen volume, patients
reported worsening of myelofibrosis symptoms and other PROs over a 6-month
time frame in this placebo population. Recognition of the debilitating symptoms of
myelofibrosis and its progressive nature suggest early intervention with effective
therapy should be considered.
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OBJECTIVES: Although NSCLC is associated with substantial symptom burden and
significantly impacts patients’ health-related quality of life (HRQoL), published
data from routine care are scarce. Improving the understanding of the HRQoL
impact of NSCLC will allow to comprehend more in-depth the benefit of treat-
ments, palliative care and differing HRQOL accross health states. METHODS: A
total 315 patients were enrolled in Australia, Belgium, Canada, France, Italy, Swe-
den, Turkey, the Netherlands and the UK to complete the EQ-5D and EQ-VAS ques-
tionnaires after receiving current treatment for 6-8 weeks. In order not to influence
patients’ perceived health, patients completed the questionnaire prior to receiving
information on their tumor status. Patient demographic, disease history, treat-
ment and adverse event data was identified from the patient chart. Utilities were
calculated by applying the UK tariffs. Patients were stratified into 12 health states
based on treatment line and treatment response status. Patients included had
advanced stage (IIIb or IV) disease, were 18 years, received 1-4 lines of treatment
having an ECOG performance status of 0-2 (scale: 0-4 with 4 being bedridden).
RESULTS: Mean age at advanced NSCLC diagnosis was 64.5 years [SD9.97] with
61.8% of patients being male, and 80.3% with stage IV disease. Fifty-two percent,
27%, and 19% of patients were on 1st, 2nd, or 3rd/4th line, respectively. Patients with
progressive disease increased with treatment line; 15% (1st line), 27% (2nd line) and
46% (3rd/4th line).Meanutility in the overall samplewas 0.65 [SD0.31].Meanutility
for progression free patients on 1st, 2nd, and 3rd/4th line treatment was 0.71
[SD0.24], 0.72 [SD0.26], and 0.62 [SD0.46], respectively.Meanutility for patients
who progressed after 1st, 2nd and 3rd/4th line treatment was 0.68 [SD0.21], 0.59
[SD0.34] and 0.46 [SD0.38], respectively. CONCLUSIONS: Both line of treatment
and progressive NSCLC disease were found to impact patients’ HRQoL assessed
using EQ-5D derived utilities.
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OBJECTIVES: Meaningful improvement in symptoms and quality of life (QOL) are
important in treating patients with small cell lung cancer (SCLC). This analysis
assessed and evaluated minimally important differences (MIDs) on the Lung Can-
cer Symptom Scale (LCSS) for patients with amrubicin- or topotecan-treated SCLC.
METHODS: A prospective, multicenter, open-label, phase III randomized design
study of 637 patients compared efficacy and safety of amrubicin to topotecan in
treatment of SCLC. LCSS data were collected at baseline, day 1 of each cycle, and
study end. The LCSS contains six symptoms (appetite, cough, dyspnea, fatigue,
hemoptysis, pain), and three items (symptom distress, interference with activity
level, global QOL). To assess clinicallymeaningful change on LCSS symptoms,MIDs
were calculated as standard deviation change from baseline for each symptom
item; for Symptom Burden Index (SBI) and Total Score, 1 standard error of mea-
surement change from baseline was utilized to adjust for reliability in the SCLC
population. RESULTS: 532 subjects with baseline and post-baseline LCSS datawere
analyzed (mean age60.1; male 58.2%). Clinically relevant minimally important
symptom and QOLworsening were similar to studies in non-small cell lung cancer
(NSCLC). Minimal values for detecting clinically meaningful differences were: for
individual symptoms, 13.7–14.5, excluding hemoptysis (4.3); for SBI, 8.7; for Total
Score, 7.2. Patients on amrubicin experienced less deterioration in individual
symptoms, less overall symptom burden, and improved QOL. The proportions of
patients with clinically relevant deterioration in coughing favored amrubicin at
Cycles 2, 6, and study end (p0.0265, p0.0026, p0.0194, respectively); at Cycles 2
and 6, but not study end, deterioration in dyspnea favored amrubicin (p0.001,
p0.0419, respectively). Similar trends favoring amrubicin were seen in the re-
maining symptoms. CONCLUSIONS: Meaningful change on the LCSS, previously
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